Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing.
Pictured: Rapport CEO Abe Ceesay/company courtesy
Rapport Therapeutics, a clinical-stage biotech aiming to develop precision medicines for neurological disorders, launched Tuesday with $100 million in Series A financing from Third Rock Ventures, ARCH Venture Partners and Johnson & Johnson Innovation (JJDC).
Rapport’s platform may target receptor-associated proteins in neurological disorders using small-molecule drugs. The company’s lead program is currently being studied in Phase I for drug-resistant seizure disorders.
Abe Ceesay is the newly appointed CEO of Rapport. Ceesay brings 20 years of experience in biopharma, as the former president of Pfizer and Bain Capital’s Cerevel Therapeutics, and before that, as CEO of Tiburio Therapeutics.
He told BioSpace Rapport’s platform differs from others that lack its precision and ability to hit specific targets.
“A lot of unmet needs exist across many neurological disorders, primarily based on the fact that current therapies are nonspecific in nature,” Ceesay said. “The platform we have at Rapport is going to change that and deliver highly specific therapies that are not only going to deliver greater efficacy to patients but also better-tolerated drugs that will allow patients to stay on therapy.”
He believes Rapport’s platform has the potential to deliver highly specific therapies that not only have greater efficacy but also better-tolerated drugs that will allow patients to stay on therapy.
The technology uses receptor-associated proteins (RAPs). Because they only exist in certain areas of the brain, they can target receptors in the specific neuroanatomical regions underlying the pathophysiology of neurological disorders.
In contrast, current treatments target proteins expressed throughout the nervous system, reducing efficacy and patient safety.
“The era of precision neuroscience is upon us, and patients’ needs have never been greater,” said Reid Huber, Ph.D., Rapport director and partner at Third Rock Ventures in a prepared statement.
Rapport’s goal is to use this platform to not only improve upon existing therapies but to discover new RAPs to develop treatments for patients with neurological disorders that currently have no treatment options.
“RAPs create multiple opportunities to develop new and better options for patients because they enable us both to introduce precision against validated targets and to access currently undruggable receptor types,” Huber said.
